

“Effective November 1, 2013, Harvard Bioscience completed the spin-off of its wholly owned subsidiary, Harvard Apparatus Regenerative Technology, Inc., into an independent, publicly traded corporation to holders of Harvard Bioscience common stock as of the October 21, 2013 record date. The information contained herein does not constitute tax advice and does not purport to be complete or describe consequences that may apply to particular categories of shareholders. Harvard Bioscience does not provide tax advice to its shareholders. The example in Form 8937 is solely for illustrative purposes and as a convenience to shareholders and their tax advisors when establishing their specific tax position. You should consult your own tax advisor as to the particular tax consequences of the spin-off of HART and related distribution to you, including potential tax consequences under US federal, state, local and non-U.S. tax laws. For US federal income tax purposes, view a PDF of the IRS Form 8937 by [clicking here](#) and view a PDF of the News Release by [clicking here](#).”